Switch theme
Sign up to access all valuation multiples
Curiox Biosystems Co Ltd is Korean Based company which brings together decades of scientific and engineering expertise in surface chemistry and life science instrumentation with the goal of overcoming critical challenges that slow the pace of life science research. The company has introduced Laminar Wash technology, which automates cell processing and enables highly reproducible and high-throughput cell analysis. The company offers various products such as LAMINAR WASH AUTO 1000 SYSTEM, Curiox Laminar Wash HT2000 System and Laminar Wash MINI System.
2018
n/a
LTM Revenue $3.7M
LTM EBITDA -$8.3M
$481M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Curiox Biosystems has a last 12-month revenue (LTM) of $3.7M and a last 12-month EBITDA of -$8.3M.
In the most recent fiscal year, Curiox Biosystems achieved revenue of $3.4M and an EBITDA of -$3.5M.
Curiox Biosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Curiox Biosystems valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.7M | XXX | $3.4M | XXX | XXX | XXX |
| Gross Profit | $2.1M | XXX | $1.9M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | -$8.3M | XXX | -$3.5M | XXX | XXX | XXX |
| EBITDA Margin | -226% | XXX | -103% | XXX | XXX | XXX |
| EBIT | -$10.2M | XXX | -$9.9M | XXX | XXX | XXX |
| EBIT Margin | -278% | XXX | -292% | XXX | XXX | XXX |
| Net Profit | -$6.8M | XXX | -$6.0M | XXX | XXX | XXX |
| Net Margin | -187% | XXX | -176% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Curiox Biosystems's stock price is KRW 41300 (or $31).
Curiox Biosystems has current market cap of KRW 667B (or $494M), and EV of KRW 650B (or $481M).
See Curiox Biosystems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $481M | $494M | XXX | XXX | XXX | XXX | $-0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Curiox Biosystems has market cap of $494M and EV of $481M.
Curiox Biosystems's trades at 141.7x EV/Revenue multiple, and -137.9x EV/EBITDA.
Equity research analysts estimate Curiox Biosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Curiox Biosystems has a P/E ratio of -72.1x.
See valuation multiples for Curiox Biosystems and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $494M | XXX | $494M | XXX | XXX | XXX |
| EV (current) | $481M | XXX | $481M | XXX | XXX | XXX |
| EV/Revenue | 131.3x | XXX | 141.7x | XXX | XXX | XXX |
| EV/EBITDA | -58.0x | XXX | -137.9x | XXX | XXX | XXX |
| EV/EBIT | -47.3x | XXX | -48.6x | XXX | XXX | XXX |
| EV/Gross Profit | 228.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -72.1x | XXX | -82.5x | XXX | XXX | XXX |
| EV/FCF | -41.0x | XXX | -65.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCuriox Biosystems's last 12 month revenue growth is 7%
Curiox Biosystems's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Curiox Biosystems's rule of 40 is -114% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Curiox Biosystems's rule of X is -209% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Curiox Biosystems and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -226% | XXX | -103% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -114% | XXX | -96% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -209% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 347% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curiox Biosystems acquired XXX companies to date.
Last acquisition by Curiox Biosystems was XXXXXXXX, XXXXX XXXXX XXXXXX . Curiox Biosystems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Curiox Biosystems founded? | Curiox Biosystems was founded in 2018. |
| Where is Curiox Biosystems headquartered? | Curiox Biosystems is headquartered in South Korea. |
| Is Curiox Biosystems publicy listed? | Yes, Curiox Biosystems is a public company listed on KRX. |
| What is the stock symbol of Curiox Biosystems? | Curiox Biosystems trades under 445680 ticker. |
| When did Curiox Biosystems go public? | Curiox Biosystems went public in 2023. |
| Who are competitors of Curiox Biosystems? | Similar companies to Curiox Biosystems include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Curiox Biosystems? | Curiox Biosystems's current market cap is $494M |
| What is the current revenue of Curiox Biosystems? | Curiox Biosystems's last 12 months revenue is $3.7M. |
| What is the current revenue growth of Curiox Biosystems? | Curiox Biosystems revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Curiox Biosystems? | Current revenue multiple of Curiox Biosystems is 131.3x. |
| Is Curiox Biosystems profitable? | Yes, Curiox Biosystems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Curiox Biosystems? | Curiox Biosystems's last 12 months EBITDA is -$8.3M. |
| What is Curiox Biosystems's EBITDA margin? | Curiox Biosystems's last 12 months EBITDA margin is -226%. |
| What is the current EV/EBITDA multiple of Curiox Biosystems? | Current EBITDA multiple of Curiox Biosystems is -58.0x. |
| What is the current FCF of Curiox Biosystems? | Curiox Biosystems's last 12 months FCF is -$11.7M. |
| What is Curiox Biosystems's FCF margin? | Curiox Biosystems's last 12 months FCF margin is -320%. |
| What is the current EV/FCF multiple of Curiox Biosystems? | Current FCF multiple of Curiox Biosystems is -41.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
